Wnt inhibitor XAV939 suppresses the viability of small cell lung cancer NCI‑H446 cells and induces apoptosis

Guo,Wenxuan; Shen,Fangzhen; Xiao,Wenjing; Chen,Jing; Pan,Fei

doi:10.3892/ol.2017.7100

Wnt inhibitor XAV939 suppresses the viability of small cell lung cancer NCI‑H446 cells and induces apoptosis

Authors:
- Wenxuan Guo
- Fangzhen Shen
- Wenjing Xiao
- Jing Chen
- Fei Pan
View Affiliations

Affiliations: Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: September 28, 2017 https://doi.org/10.3892/ol.2017.7100
Pages: 6585-6591
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer due to a fast tumor doubling time and early hematogenous spread. Advances in the treatment of non‑small cell lung cancer using targeted therapies having been made, but no targeted drugs for SCLC have been approved. The Wnt signaling pathway is associated with tumor progression and metastasis; therefore, the inhibition of Wnt/β‑catenin signaling is a strategy for anticancer drugs. Tankyrase 1 (TNKS1) is overexpressed in a number of types of cancer and XAV939 is a small molecule inhibitor of TNKS1 which may inhibit tumor growth. The present study aimed to investigate the potential molecular mechanisms underlying XAV939‑induced suppression of the viability of SCLC cells. MTT assays were used to determine the viability‑inhibition rate of cells and to identify the drug concentration which optimally inhibited cell viability. Flow cytometry was used to determine whether XAV939 induced apoptosis of SCLC cells, and to analyze the effect of the drug on the cell cycle. The results of the present study identified that XAV939 inhibited the viability of NCI‑H446 cells in a dose‑dependent manner, but cisplatin inhibited NCI‑H446 cell viability in a time‑ and dose‑dependent manner. The combination of XAV939 and cisplatin exhibited a slightly more pronounced inhibition of cell viability at an increased dose of XAV939. In addition, XAV939 markedly induced cell apoptosis of the SCLC cell line H446 by increasing the proportion of cells in the G0/G1 phase, leading to inhibition of the cell cycle. The results of the present study indicated that XAV939 inhibited the viability of the NCI‑H446 SCLC cell line by inducing cell apoptosis through the Wnt signaling pathway. Therefore, XAV939 may be useful for the treatment of SCLC.

View Figures

View References

1	Byers LA and Rudin CM: Small cell lung cancer: Where do we go from here? Cancer. 121:664–672. 2015. View Article : Google Scholar : PubMed/NCBI
2	Merrill RM, Henson DE and Barnes M: Conditional survival among patients with carcinoma of the lung. Chest. 116:697–703. 1999. View Article : Google Scholar : PubMed/NCBI
3	Gustafsson BI, Kidd M, Chan A, Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
4	Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings KE, Bee T, Spinella MJ, Dmitrovsky E and Freemantle SJ: Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer. 9:3832009. View Article : Google Scholar : PubMed/NCBI
5	You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F and Jablons DM: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 23:6170–6174. 2004. View Article : Google Scholar : PubMed/NCBI
6	Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ and Morrisey EE: Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 121:1935–1945. 2011. View Article : Google Scholar : PubMed/NCBI
7	Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
8	Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
9	Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
10	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
11	Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 4:a0080522012. View Article : Google Scholar : PubMed/NCBI
12	Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E and Freemantle SJ: Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 13:2112013. View Article : Google Scholar : PubMed/NCBI
13	Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
14	Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, et al: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 5:100–107. 2009. View Article : Google Scholar : PubMed/NCBI
15	MacNamara B, Wang W, Chen Z, Hou M, Mazur J, Gruber A and Porwit-MacDonald A: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas. Haematologica. 86:386–393. 2001.PubMed/NCBI
16	Klapper W, Krams M, Qian W, Janssen D and Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer. 89:713–719. 2003. View Article : Google Scholar : PubMed/NCBI
17	Gelmini S, Poggesi M, Distante V, Bianchi S, Simi L, Luconi M, Raggi CC, Cataliotti L, Pazzagli M and Orlando C: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett. 216:81–87. 2004. View Article : Google Scholar : PubMed/NCBI
18	Gelmini S, Poggesi M, Pinzani P, Mannurita SC, Cianchi F, Valanzano R and Orlando C: Distribution of Tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage. Oncol Rep. 16:1261–1266. 2006.PubMed/NCBI
19	Gelmini S, Quattrone S, Malentacchi F, Villari D, Travaglini F, Giannarini G, Della Melina A, Pazzagli M, Nicita G, Selli C and Orlando C: Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: Preliminary experience. Clin Chem Lab Med. 45:862–866. 2007. View Article : Google Scholar : PubMed/NCBI
20	Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T and Shervington L: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 1134:45–52. 2007. View Article : Google Scholar : PubMed/NCBI
21	Tian X, Hou W, Bai S, Fan J, Tong H and Xu H: XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1. Int J Oncol. 45:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
22	Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, et al: A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72:2822–2832. 2012. View Article : Google Scholar : PubMed/NCBI
23	Bilir B, Kucuk O and Moreno CS: Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 11:2802013. View Article : Google Scholar : PubMed/NCBI
24	Jahromi Zare M, Ranjbarian P and Shiravi S: Cytotoxicity evaluation of Iranian propolis and calcium hydroxide on dental pulp fibroblasts. J Dent Res Dent Clin Dent Prospects. 8:130–133. 2014.PubMed/NCBI
25	Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M and Puri N: Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One. 8:e783982013. View Article : Google Scholar : PubMed/NCBI
26	Moon RT: Wnt/β-catenin pathway. Science's STKE. 2005:cm12005.
27	Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
28	Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, Lundholm L and Viktorsson K: DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer. 15:6282015. View Article : Google Scholar : PubMed/NCBI
29	Shi Y, He B, You L and Jablons DM: Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin. 28:1499–1504. 2007. View Article : Google Scholar : PubMed/NCBI
30	Shao W and Wang W: Experimental and basic research affect telomerase inhibitor XAV939 joint nedaplatin on HeLa cell proliferation and apoptosis. Maternal and Child Health Care of China. 19:1001–4411. 2014.
31	Partanen JI, Nieminen AI, Mäkelä TP and Klefstrom J: Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci USA. 104:pp. 14694–14699. 2007, View Article : Google Scholar : PubMed/NCBI
32	Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, et al: Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest. 88:98–111. 2008. View Article : Google Scholar : PubMed/NCBI
33	Jirawatnotai S, Hu Y, Livingston DM and Sicinski P: Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 72:4289–4293. 2012. View Article : Google Scholar : PubMed/NCBI
34	Yang Y, Mallampati S, Sun B, Zhang J, Kim SB, Lee JS, Gong Y, Cai Z and Sun X: Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett. 333:9–17. 2013. View Article : Google Scholar : PubMed/NCBI
35	Dihlmann S and von Knebel Doeberitz M: Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 113:515–524. 2005. View Article : Google Scholar : PubMed/NCBI